Life Science Nation Newsletter  | August 11,  2016  |  Issue 174

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Aug. 4  - Aug. 10)
Focuses on Diseases of the Eye
Seeks Life Science Opportunites in the US and Europe
Seeks Immunology Assets Worldwide
Seeks US Life Science and Healthtech Deals
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Videos
RESI Landing on MaRS

RESI on MaRS Investors Panel

By Lucy Parkinson, Director of Research, LSN

Boston is often called the center of the global biotechnology industry, and it's therefore no surprise that investors are flocking to RESI Boston to meet with early stage drug development entrepreneurs. LSN has gathered a panel of 5 top investors in therapeutics to share their tips and insights on the assessment of novel therapeutic technologies.

These five panelists will be sharing their expertise with RESI's audience:
  • Charlotte Hubbert, Program Investment Officer, Bill & Melinda Gates Foundation
  • Kush Parmar, Partner, 5am Ventures
  • Erin Washington, Manager, Transactions & Business Analysis, Johnson & Johnson Innovation
  • Bard Geesaman, Managing Director, MPM Capital
  • Mark Day, Senior Director, Corporate Development, Alexion
By Caitlin Kramer, Research Analyst, LSN

Incubators, accelerators, and other organizations are increasingly emerging as conduits for early stage life science companies to plug in to pre-existing networks, infrastructure, and capital.  Entrepreneurs may find themselves faced with choosing whether to participate in such programs, and weigh and evaluate the benefits a given program may offer in helping them achieve their goals. At RESI on MaRS, five panelists from different groups in this sector discussed the topic from their own unique positions, each presenting the specialties and area of focus of their organization.

Moderated by Rebecca Yu, Head of JLABS @ Toronto, Johnson & Johnson Innovation (JLABS), panelists include
  • Christopher Kim, Managing Partner, Korea-Seoul Life Sciences Fund (KSL) and Novatio Ventures
  • Dianne Carmichael, Managing Director of Health, MaRS Discovery District
  • Gordon Kurtenbach, Senior Director of Research, Autodesk
  • Linda Maxwell, Founder and Managing Director, Biomedical Zone
Each model has a unique value proposition which lies in its approach to network-building

Across the board, incubators, accelerators, and other models act as hubs for connecting startups to a wide range of entities; but which entities...

   
By Nono Hu, Director of Marketing, LSN

Once you have a global target list of investors as we outlined in last week's chapter, you will want to begin going outbound and contacting these groups. With this week's edition of the summer reading series, we explain what goes into an effective phone canvassing campaign.

"Chapter 10: Phone Canvassing" goes through the process of reaching out to potential investors effectively via the phone. Now the idea of contacting investors, or anyone for that matter, via a cold call may sound daunting to many fundraising entrepreneurs; however, in the highly competitive marketplace for early stage investment, entrepreneurs should use this and all professional tactics available to them in order to separate from the crowd and garner more attention from potential investors...